Imperial Capital, LLC Announces the Launch of a New Vertical in the Healthcare Royalty Monetization Sector

LOS ANGELES, Oct. 26, 2020 /PRNewswire/ -- Imperial Capital, LLC ("Imperial Capital) announced today the firm has launched a new vertical within its Investment Banking and Corporate Finance unit regarding Healthcare Royalty Monetization. Royalty based financings allow for a patent holder to receive an upfront payment based on future revenue streams associated certain drugs, small molecule chemical compounds, formulation methods or healthcare related instruments .  Alternative financial structures such as  Royalty Monetization will support continued growth in the Life Sciences Industry. Imperial Capital's long standing relationships in the corporate and institutional investment community will allow for a swift and efficient start to this new vertical.

"Imperial Capital views the Healthcare and Pharmaceutical Royalty Monetization vertical as a natural fit given it's structural strengths and experience with royalties and yield-based instruments" said Chris Shepard, Co-Head of Investment Banking and Capital Markets.

Imperial Capital recently acted as Exclusive Financial Advisor to a private company regarding their sale of a significant Trademark and Patent Royalty associated with Vimpat, a highly effective prescription drug used as a monotherapy to treat partial?onset seizures associated with Epilepsy.  Carter Ledyard & Milburn LLP acted as lead counsel to the seller.

"This transaction demonstrates Imperial Capital's expertise across various industries sectors as well as a deep knowledge of royalty related income streams" said Ken Morris, Managing Director who led the engagement and transaction execution.

About Imperial Capital, LLC

Imperial Capital, LLC is a full-service investment bank offering a uniquely integrated platform of comprehensive services to institutional investors and middle market companies. We offer sophisticated sales and trading services to institutional investors and a wide range of investment banking advisory, capital markets and restructuring services to middle market corporate clients. Paired with our proprietary research and sales & trading desk analysis, we provide investment analysis across an issuer's capital structure, including bank loans, debt securities, the hybrid/bank capital marketplace (through our ELP Framework), post-reorganization equities, special situations claims and listed and unlisted equities. Our comprehensive and integrated service platform, expertise across the global capital structure, and deep industry sector knowledge enable us to provide clients with research driven ideas, superior advisory services, and trade execution. We are quick to identify opportunities under any market conditions and we have a proven track record of offering creative, proprietary solutions to our clients. Imperial Capital, LLC has three principal businesses: Investment Banking, Institutional Sales & Trading and Institutional Research. More information about Imperial Capital, LLC can be found at www.imperialcapital.com.

For additional information regarding Imperial Capital's Healthcare and Pharmaceutical Royalty Monetization practice, please contact:
Ken Morris
212 35 9755 (office)
917 515 8201 (cell)
[email protected]

SOURCE Imperial Capital, LLC